The three-dimensional structure of protein kinase C interacting protein 1 (PKCI-1) has been solved to high resolution by x-ray crystallography using single isomorphous replacement with anomalous scattering. The gene encoding human PKCI-1 was cloned from a cDNA library by using a partial sequence obtained from interactions identified in the yeast two-hybrid system between PKCI-1 and the regulatory domain of protein kinase C-f3. The PKCI-1 protein was expressed in Pichia pastoris as a dimer of two 13.7-kDa polypeptides. PKCI-1 is a member of the HIT family of proteins, shown by sequence identity to be conserved in a broad range of organisms including mycoplasma, plants, and humans. Despite the ubiquity of this protein sequence in nature, no distinct function has been shown for the protein product in vitro or in vivo. The PKCI-1 protomer has an cx+f3 meander fold containing a five-stranded antiparallel sheet and two helices. Two protomers come together to form a 10-stranded antiparallel sheet with extensive contacts between a helix and carboxy terminal amino acids of a protomer with the corresponding amino acids in the other protomer. PKCI-1 has been shown to interact specifically with zinc. The three-dimensional structure has been solved in the presence and absence of zinc and in two crystal forms. The structure of human PKCI-1 provides a model of this family of proteins which suggests a stable fold conserved throughout nature.
A protein kinase C (PKC) inhibitory protein designated PKCI-1 (for PKC interacting protein 1) was initially purified from bovine brain as a potent inhibitor of protein kinase C (1) (2) (3) (4) . Since that time, other investigators have characterized a protein similar to bovine PKCI-1 from other organisms and have not been able to demonstrate inhibitory effect on PKC activity (ref. 5 ; M.G.K. and C.D.L., unpublished observations). In addition, some doubt has been cast on the physiological relevance of PKC inhibition by bovine PKCI-1 (6) . Because of subsequent results obtained in the yeast two-hybrid system (described below), we have designated this protein PKC interacting protein, employing the same acronym PKCI-1.
PKCI-1 has been shown to interact with the regulatory domain of PKC-3 in the yeast two-hybrid system (M.G.K., unpublished observations). PKCI-1 has also been shown to interact with the ataxia-telangiectasia group D (ATDC) protein in the yeast two-hybrid system (7) . The ATDC protein is implicated in the human genetic disease ataxia-telangiectasia. In addition, an open reading frame (ORF) encoding a cyanobacterial PKCI-1 homologue has been identified, and inactivation of this ORF in cyanobacteria results in a slow growth phenotype for this organism (8) . These results suggest a possible role for PKCI-1 in signal transduction pathways.
Several DNA ORFs coding for a protein similar to bovine PKCI-1 have been identified in a broad range of organisms including mycoplasma, plants, and humans (9, 10) . Some have been grouped into the HIT protein family and into a novel class of zinc-binding proteins. The acronym HIT refers to a conserved triad of histidines that is thought to interact with zinc.
PKCI-1 from bovine brain and maize were purified as heat stable proteins and shown to specifically bind zinc (1-3, 5, 11) . The zinc-binding motif of PKCI-1 was initially identified by synthesizing peptides from various regions of PKCI-1 and demonstrating their ability to specifically bind zinc. A histidine-rich peptide (His-Val-His-Leu-His) near the carboxy terminal end of the polypeptide was identified as having the ability to bind zinc in the micromolar range. In addition, the His-Xaa-His-Xaa-His motif is almost completely conserved throughout this family of proteins.
Zinc and metal free (apo) forms of human PKCI-1 have been crystallized and solved to high resolution using x-ray crystallographic methods. Structural and sequence analyses have identified elements of these structures that are conserved throughout a broad range of organisms. The presumed structural similarities of PKCI-1 between organisms has implications with respect to the mechanism of zinc binding and for the potential surfaces of the molecule which may be involved in protein/protein interactions and the in vivo functions of PKCI-1.
MATERIALS AND METHODS
Cloning. A human PKCI-1 cDNA sequence was identified by using the yeast two-hybrid system during studies designed to isolate proteins that interact with the regulatory domain of PKC-(3. The yeast two-hybrid screen was conducted by using a fusion between LexA and the amino-terminal 317 amino acids of PKC-(3 (12) as a probe. By screening 300,000 colonies expressing a HL-60 cDNA library fused to the Gal4 activation domain (13), we identified a single colony that activated the LacZ reporter gene only in the presence of the bait plasmid but was unable to activate LacZ expression when tested using LexA alone. This clone was identified by sequence alignment with bovine PKCI-1 as a partial human PKCI-1 cDNA lacking the amino-terminal 31 amino acids, such that the Gal4 activation domain was fused to the sequence encoding isoleucine 32 of human PKCI-1. The entire PKCI-1 cDNA coding sequence was obtained from a HL-60 Zap library (Stratagene) by hybridization to a polymerase chain reaction (PCR) generated probe (14) , which amplified sequences of human PKCI-1 encoding amino acids 36-54.
Antibodies. Polyclonal antibodies were generated against a bacterially expressed glutathione-S-transferase (GST)/PKCI-1 fusion protein by injecting the factor Xa cleaved-PKCI-1 component of the fusion protein into rabbits. The antiserum was affinity purified by passing it over a cyanogen bromide-activated sepharose column to which the GST/PKCI-1 fusion protein was Abbreviations: PKC, protein kinase C; PCKI-1, PKC interacting protein 1; ORF, open reading frame; 2-ME, 2-mercaptoethanol. Data deposition: The sequence reported in this paper has been deposited in the GenBank data base (accession no. U51004). Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, Chemistry Department, Brookhaven National Laboratory, Upton, NY 11973 (references lkpa, lkpb, lkpc). This information is available immediately.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. covalently coupled. Western blot analysis of several cell types indicated that the antibody raised against bacterially expressed PKCI-1 detected a 14-kDa band, which is consistent with the expected molecular weight of PKCI-1. PKCI-1 was detected in several human tumor cell lines including breast, esophageal and colon cancer cells, promyelocytic leukemia cells (HL-60), and HeLa cells. This antibody also detected a protein of the expected molecular weight in primary human skin fibroblasts, mouse NIH 3T3 fibroblasts, rat 6 fibroblasts, K22 rat liver epithelial cells, bovine aortic endothelial cells, HC11 mouse mammary epithelial cells, rat intestinal epithelial cells, IEC18, and several other cell lines (data not shown). Other studies (2, 5) have shown that PKCI-1 is present in a wide variety of tissues, indicating that it is expressed across a broad range of species and tissue.
Expression and Purification. The human PKCI-1 cDNA was subcloned into pHIL-D5, a vector for use in the yeast Pichia pastoris overexpression system (Invitrogen). It was hoped that certain isoforms of PKC might be stabilized in this overexpression system by forming a complex with PKCI-1. Therefore, several PKC isoforms were cloned into this vector with restriction sites engineered either 5' or 3' of the ORF of the PKC isoform of interest. The plasmid was constructed so the preceding ORF would include a termination codon, a frame shift, and the start codon of the subsequent ORF. In this way, it was hoped that a mRNA chimera would produce both the PKC isotype of interest and the PKCI-1 gene product in equamolar amounts. Although active forms of PKC were expressed in this system, no PKC-PKCI-1 complexes were observed in extracts of these cells (C.D.L., unpublished observations).
A MUT-strain of P. pastoris carrrying the pHIL-D5 genomic insertion containing human PKCI-1 and PKC-a cDNA sequences was grown in minimal media in 1.5-liter flasks in 12-liter batches for 2 to 3 days or until the culture reached saturation. The culture was centrifuged and the pellet resuspended in 25% of the original volume in minimal medium containing 0.5% methanol, and grown for an additional 2 days. The cells were again centrifuged and resuspended in a buffer containing 20 mM Tris (pH 8.0), 10 mM 2-mercaptoethanol (2-ME), 1 mM phenylmethylsulfonyl flouride, 1 mM EDTA, 0.1 mM pepstatin, and 20% sucrose. The cell suspension was placed into a bead beater (Biospec Products, Bartlesville, OK) and lysed using eight 30-sec pulses. The lysate was cleared by centrifugation and dialyzed against 20 mM Tris (pH 8.0), 1 mM EDTA, 5 mM 2-ME, and 0.1 mM phenylmethylsulfonyl flouride (buffer A). The lysate was loaded onto a Q sepharose 26/10 column (Pharmacia) for batch elution. A 100 mM NaCl batch elution in buffer A eluted PKCI-1 from this column. PKCI-1 could be visualized in the crude lysate and through purification by SDS/PAGE. The fraction containing PKCI-1 was dialyzed against buffer A and placed onto a Mono Q 10/10 column and eluted using a 200 ml gradient from 0 to 80 mM NaCl in buffer A. The fractions containing PKCI-1 were concentrated and loaded onto a Hiload 26/60 Superdex 200 column (Pharmacia) in buffer A. The protein eluted as a dimer from this column and was reapplied to the Mono Q 10/10 column and eluted with a gradient of 0 to 80 mM NaCl. This protocol yielded 2-3 mg of >95% pure apo-PKCI-1 (without zinc) as analyzed by SDS/PAGE. The protocol was modified to purify zinc-PKCI-1 by substituting 50 ,uM zinc acetate for 1 mM EDTA in buffer A throughout the purification. Both preparations could be stored at -80°C after flash freezing. Zinc-PKCI-1 had to be stored at 0.5 mg/ml to prevent aggregation. Apo-PKCI-1 could be stored at or above 10 mg/ml. In both instances, the final storage buffer included 5 mM Tris (pH 7.5) and 1 mM 2-ME.
Crystallization. Microcrystals of apo-PKCI-1 were obtained using a partial factorial screen (ref. 15 ; Hampton Research). Final conditions thatyielded single crystals included 13-18% PEG 8000 and 100 mM sodium cacodylate pH 6.5 at 20°C. Crystallizations were set up using 10 mg of apo-PKCI-1 per ml and 3-6 mg of zinc-PKCI-1 per ml. Zinc-PKCI-1 is concentrated just before the protein is set up for crystallization. Hanging drops containing the zinc-PKCI-1 precipitated immediately upon addition of the well solution. Crystals nucleated from the dense precipitate and as they grew, they slowly dissolved the precipitate around them. In several cases this occurred until all of the precipitate redissolved and the drop contained only crystalline material. In contrast, hanging drops containing apo-PKCI-1 remained clear until crystals appeared in the drops.
Crystals P212121. The P21 crystal has pseudo P21212 symmetry and ranges in degree of its false symmetry from crystal to crystal. Data Collection and Structure Determination. Four data sets were collected and used to solve and analyze the structure of PKCI-1. These included a data set collected on a zinc-PKCI-1 P212121 crystal, an apo-PKCI-1 P212121 crystal, an apo-PKCI-1 P21 crystal into which 0.1 mM zinc acetate had been soaked, and a zinc-PKCI-1 P212121 crystal derivatized with Hg(CN)2. Single isomorphous replacement with anomalous scattering (SIRAS) phases were calculated and interpretable electron density was generated using the zinc P212121 and mercurated zinc P212121 data sets (Table 1 , Fig. 1 ). The current R value for the zinc-PKCI-1 model in space group P212121 is 19.2% and the free R is 26.1% from 10.0 to 2.0 A. The apo-PKCI-1 model in space group P212121 has a current R value from 10.0 to 2.0 A of 18.7% with a free R of 24.8%. The model for apo-PKCI-1 in space group P21 into which 0.1 mM zinc acetate has been soaked and has a current R value of 21.7% and a free R of 30.9 from 7.0 to 2.2 A. The three structures of PKCI-1 have no interpretable density for amino acids 1-13 although significant nonwater density could be observed in several of the maps for amino acids 10-13.
Amino Terminal Sequencing, Proteolysis, and Electrospray Mass Spectroscopy. Several methods were employed to determine the composition of the amino terminal residues in PKCI-1 due to the lack of interpretable electron density in all three models. Amino terminal sequencing was done on zinc and apo-PKCI-1. In both cases, no sequence information could be obtained due to a presumed blockage at the amino terminus by a posttranslational modification. Bovine PKCI-1 has been shown to be acetylated on the second amino acid (3). Stable fragments of PKCI-1 -1 kDa smaller than full length PKCI-1 were obtained after proteolysis by subtilisin or trypsin. Amino terminal sequencing of these fragments showed that cleavage had occurred after Gln-9 with subtilisin and Lys-7 with trypsin. To determine the composition of the full length protein, zinc-PKCI-1 was sent to the Howard Hughes Mass Spectrometer Facility for analysis by electrospray mass spectroscopy. The molecular weight of PKCI-1 was determined to be 13712.9 atomic mass units with a second peak at 13789.5 atomic mass units. The calculated molecular weight for PKCI-1 acetylated on amino acid 2 is 13712.6 atomic mass units. The second peak was determined to be a 2-ME adduct of the acetylated protein, a product seen previously by mass spectroscopy (22) . The acetylation of human PKCI-1 in the P. pastoris yeast expression system demonstrates the ability of this system to mimic a higher eukaryote in its posttranslational modifications of this protein in the cell.
RESULTS AND DISCUSSION
Overall Folding. The folding topology of PKCI-1 exhibited in all three refined structures can be described as a general a+ (3type and further subclassed into an a+f3 meander fold (23) (Fig. 2) . Each protomer contains a five-stranded antiparallel sheet and two helices. In a protomer, helix A (residues 18-24) packs on one side of its five-stranded antiparallel sheet and helix B (residues Mean FOM** 0.457
Statistics are listed for the four data sets used in the structure determination and analysis of PKCI-1. A multiwavelength anomalous diffraction (MAD) data set was collected to 2.0 A using a zinc-PKCI-1 P212121 crystal at 110 K in an attempt to utilize the anomalous signal of zinc to derive phases capable of phasing the protein electron density. These data were collected on Howard Hughes beamline X4A at Brookhaven National Laboratory. Analysis of the MAD data set indicates that no interpretable anomalous signal is present. Two other data sets were collected on an apo-PKCI-1 P212121 crystal and an apo 0.1 mM zinc soaked P21 crystal at 110K. A data set complete to 2.2 Awas collected using a RAXIS-II and modified Supper mirrors at Columbia on a P212121 zinc crystal at 110 K derivitized with 1 mM Hg(CN)2 and analyzed against the peak wavelength from the P212121 MAD data set. All data sets were processed using DENZO (16) with subsequent data reduction performed using the CCP4 program suite (17) . Two mercury positions were immediately interpretable in difference Pattersons. SIR phases were calculated using MLPHARE and difference Fourier analysis revealed two additional mercury positions. SIRAS phases were calculated using the four positions and analysis of the resulting electron density maps showed that good experimental phases could be determined by this method. An inverse beam data set was collected to obtain a complete data set of Bijvoet pairs to high resolution. Phasing and interpretable electron density to 2.25 A was obtained (Fig. 1 ) whereupon the initial model was traced within a day using the bones and lego options in o ( Fig. 1) (18) . Each monomer, there is a dimer in the asymmetric unit was traced independently. All models were refined using X-PLOR (19) using the cross-validation test (20) . Phase combination to 2.25 X with partial model and experimental SIRAS phases was used until all ordered amino acids were positioned. Refinement was extended to 2.0 A whereupon water molecules were added. NCS restraints were not used with the dimer at any time during refinement. A data set was collected on an apo-PKCI-1 P212121 crystal at beamline X4A to 2.0 A. A partial zinc-PKCI-1 model was used between 10 and 2.5 A in rigid body refinement against the apo data with an initial R value of 32.1%. Refinement was completed using 2Fo-Fc, Fo-Fc maps with model phases, and subsequently extended to 2.0 A with no NCS restraints. A molecular replacement solution using AMORE (21) was found for the P21 data using the zinc-PKCI-1 structure as the search model between 8 and 3 A. This solution was initially accomplished with the P21 data reduced in spacegroup P21212. The R value for this solution is 44% with a correlation of 37 although when refined in X-PLOR, the R value does not drop below 30% and the free R remains high. When a self-rotation of this data reduced in space group P1 was analyzed, it is observed that the pseudo 21 axis and 2-fold axis origin peaks differed in height from the true 21 axis origin peak. A molecular replacement solution was determined using two search models, now two dimers in the asymmetric unit, with a fitted R value from AMORE of 33% with a correlation coefficient of 70 from 8 to 3 A. The model was refined with no NCS restraints. All models underwent one round of simulated annealing in X-PLOR with positional refinement being used for all subsequent rounds. Weights on x-ray terms in all refinements were chosen to be less or equal to half the value suggested by X-PLOR.
*Rsym = SW -(I)I/II, where I = observed intensity, and (I) = average intensity.
tMFID (mean fractional isomorphous difference) = II[Fphl -FpI/114Fpj, where Fp = protein structure factor amplitude and IFphl = heavy-atom derivative structure factor amplitude. t1, R based on 95% of the data used in refinement. §Rfree, R based on 5% of the data withheld for the cross-validation test.
1Phasing power = root-mean-square (IFhI/E), where [Fhl = heavy-atom structure factor amplitude and E = residual lack of closure error. "Rc = II[Fh(obs)l -IFh(calc)II/1IFh (obs)l for centric reflectionswhere IFh(obs)I = observed heavy atom structure factor amplitude, and IFh(calc)I = calculated heavy-atom structure factor amplitude. **Mean FOM = figure of merit. ttLeast squares fitted rms deviations (rmsd) from noncrystallographic symmetry (ncs) between protomers in the asymmetric unit. 18-23) and B (residues 71-86) and ,B elements numbered 1 (residues 31-35), 2 (residues 38-42), 3 (residues 50-56), 4 (residues 94-100), and 5 (residues 111-118). These figures were generated using SETOR (24 Mycobacterium laprae (U15187), and Saccharomyces cerevisiae (4). (C) Orthogonal view to B depicting the molecular surface of PKCI-1 and its electrostatic potential contoured at ±2.5 kbT/e (kbT being the product of the Boltzmann constant and the temperature, and e is the charge of an electron). Red depicts negative electrostatic potential and blue depicts the positive electrostatic potential. Acidic residues on the surface of PKCI-1 conserved in higher eukaryotes include residues 34-36 and 67-71. Acidic residues conserved through almost all organisms include 34-36, 67, and 68. solution and in crystallization experiments, no structural manifestations of these properties can be detected. As such, we propose that the crystal structure of PKCI-1 determined in the presence of zinc is similar to the apo structure because the crystallization conditions act to force PKCI-1 into the apo conformation. Proteolysis experiments were done on the apo and zinc forms of the protein using subtilisin. A protease-resistant form of PKCI-1 was formed by loss of the amino terminal nine amino acids. Truncated apo-PKCI-1 is stable over long periods of time in the presence of protease whereas truncated zinc-PKCI-1 is degraded over time without accumulation of other stable fragments as detectable by SDS/PAGE (C.D.L., unpublished observations). It has been observed before, namely by circular dichroism, that PKCI-1 exhibits a change in secondary structure over time in the presence of zinc (3, 5) . Limited proteolysis of apo and zinc forms of the enzyme indicate that the zinc form of the protein is alternatively folded in comparison to apo-PKCI-1 and undergoes nonspecific degradation in the presence of a proteolytic enzyme, suggesting that zinc-PKCI-1 may adopt a conformation unlike that observed in our crystal structures.
Structural Basis for Zinc Binding. Analysis of the PKCI-1 structures and related sequences indicated that the residues involved in zinc binding may not be those initially identified by peptide mapping (3) . We compared several protein sequences of PKCI-1 family members in light of our structural information. It became obvious that the histidyl residues poised to interact with zinc are most likely His-112, His-114, and His-51 in the structures reported here. His-110, a histidine initially thought to interact with zinc, is not completely conserved among family members and is not in a position where it could easily interact with His-112 and His-114. His-51 is completely conserved throughout the family and is proximal to His-112 and His-114 which are also completely conserved (Fig. 3A) . The alternative folding suggested for zinc-PKCI-1 in solution could be explained by having His-51, His-112, and His-114 rearrange to bind zinc. It should be noted that many of the conserved residues surrounding the three histidines are hydrophobic in character and exposed to solvent.
Structural and Sequence Similarity in the PKCI-1 Family of Proteins. Sequence alignments between PKCI-1 family members ranging from mycoplasma to plants to humans reveal that this protein is extremely well conserved throughout nature. Amino acid sequence identity for the entire coding region between human and bovine PKCI-1 (94.4%), between human and maize (53.0%), and between human and mycoplasma PKCI-1 (30.6%) indicate that the structure of this protein is well conserved in a broad range of life forms (Fig. 3A) . In addition, it appears that many of the residues on the surface of the protein are very well conserved throughout this range of organisms, implying that PKCI-1 may share common functional partners in all of these organisms (Fig. 3B) . Although no distinct activity can be attributed to PKCI-1 at this time, it is intriguing to observe this level of identity in such a broad range of organisms. A possible common feature of PKCI-1 is the electrostatic distribution around the molecule (Figure 3c ). Several conserved and exposed acidic residues on one face of the protein contribute to form a large negative electrostatic field. Although it has yet to be proven that these residues are important for PKCI-1 function in vivo, the asymmetry of charge distribution for the molecule is quite striking.
The structural elucidation of human PKCI-1 provides the first three-dimensional model for this ubiquitous family of proteins. Armed with this structural information, the search for functional roles for this protein in vivo can now be designed with precision.
Note. Recently a PKCI-1 homologue has been cloned from Homo sapiens as the putative tumor suppressor gene at locus 3pl4.2, a region often homozygously deleted in many esophageal, stomach, and colon tumors and tumor-derived cell lines. This PKCI-1 homologue has been termed FHIT by Ohta et al. (26) The hypothetical translation product of FHIT has -50% identity to the Schizosaccharomycespombe PKCI-1 homologue which has been shown to be a diadenosine 5',5"'-P1,P4-tetraphosphate (Ap4A) asymmetrical hydrolase by Robinson et al. (27) , thus suggesting that FHIT is also an Ap4A asymmetrical hydrolase.
Human PKCI-1 is not an Ap4A asymmetrical hydrolase; however, substrates have been identified for which human PKCI-1 exhibits hydrolytic activity (C.D.L., unpublished results). Although human PKCI-1 has only -25% identity with FHIT, the sequence identity corresponds with those regions highlighted in Figs. 3 A 
